-
Posted: January 27th, 2017, 3:00am GMT
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Melanoma of Unknown Primary; Mucosal Melanoma; Unresectable Cutaneous Melanoma; Unresectable Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: January 20th, 2017, 3:00am GMT
Conditions: Melanoma
Interventions: Drug: Dabrafenib; Drug: Trametinib; Drug: Phenformin
Sponsors: Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital; Weill Medical College of Cornell University
Active, not recruiting
-
Posted: January 16th, 2017, 3:00am GMT
Conditions: Neuroendocrine Tumors
Sponsors: Société Française d'Endoscopie Digestive
Active, not recruiting
-
Posted: January 11th, 2017, 3:00am GMT
Conditions: Prostate Cancer
Sponsors: Mayo Clinic
Active, not recruiting
-
Posted: January 6th, 2017, 3:00am GMT
Conditions: Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell Lymphoma
Interventions: Drug: Pembrolizumab
Sponsors: UNICANCER; National Cancer Institute, France; Ligue contre le cancer, France; Merck Sharp & Dohme LLC
Completed
-
Posted: January 2nd, 2017, 3:00am GMT
Conditions: Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Lenvatinib; Other: Quality-of-Life Assessment
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed